Display options
Cite
Grillo R, Melo NF, Moraes CM, et al. Hydroxymethylnitrofurazone:dimethyl-beta-cyclodextrin inclusion complex: a physical-chemistry characterization. J Biol Phys. 2008;33(5):445-53doi: 10.1007/s10867-008-9054-7.
Grillo, R., Melo, N. F., Moraes, C. M., Rosa, A. H., Roveda, J. A., Menezes, C. M., Ferreira, E. I., & Fraceto, L. F. (2007). Hydroxymethylnitrofurazone:dimethyl-beta-cyclodextrin inclusion complex: a physical-chemistry characterization. Journal of biological physics, 33(5), 445-53. https://doi.org/10.1007/s10867-008-9054-7
Grillo, Renato, et al. "Hydroxymethylnitrofurazone:dimethyl-beta-cyclodextrin inclusion complex: a physical-chemistry characterization." Journal of biological physics vol. 33,5 (2007): 445-53. doi: https://doi.org/10.1007/s10867-008-9054-7
Grillo R, Melo NF, Moraes CM, Rosa AH, Roveda JA, Menezes CM, Ferreira EI, Fraceto LF. Hydroxymethylnitrofurazone:dimethyl-beta-cyclodextrin inclusion complex: a physical-chemistry characterization. J Biol Phys. 2007 Dec;33(5):445-53. doi: 10.1007/s10867-008-9054-7. Epub 2008 Feb 27. PMID: 19669530; PMCID: PMC2565764.
Copy Download .nbib Format: NLM
Share it on

J Biol Phys. 2007 Dec;33(5):445-53. doi: 10.1007/s10867-008-9054-7. Epub 2008 Feb 27.

Hydroxymethylnitrofurazone:dimethyl-beta-cyclodextrin inclusion complex: a physical-chemistry characterization.

Journal of biological physics

Renato Grillo, Nathalie Ferreira Silva Melo, Carolina Morales Moraes, André Henrique Rosa, José Arnaldo Frutuoso Roveda, Carla M S Menezes, Elizabeth Igne Ferreira, Leonardo Fernandes Fraceto

Affiliations

  1. Department of Environmental Engineering, State University of São Paulo, Campus Sorocaba, CEP 18087-180 Sorocaba, São Paulo, Brazil.

PMID: 19669530 PMCID: PMC2565764 DOI: 10.1007/s10867-008-9054-7

Abstract

Hydroxymethylnitrofurazone (NFOH) is active against Trypanosoma cruzi; however, its low solubility and high toxicity precludes its current use in treatment of parasitosis. Cyclodextrin can be used as a drug carrier system, as it is able to form inclusion (host-guest) complexes with a wide variety of organic (guest) molecules. Several reports have shown the interesting use of modified beta-cyclodextrins in pharmaceutical formulation, to improve the bioavailability of drugs and to decrease their toxicity. The aim of this work was to characterize inclusion complexes formed between NFOH and dimethyl-beta-cyclodextrin (DM-beta-CD) by complexation/release kinetics and solubility isotherm experiments using ultraviolet (UV)-visible spectrophotometry and by the measurement of the dynamics information obtained from T(1) relaxation times and diffusion (DOSY) experiments using nuclear magnetic resonance (NMR) spectroscopy. The complex was prepared at different NFOH and DM-beta-CD molar ratios. The UV-visible measurements were recorded in a spectrophotometer, and NMR experiments were recorded at 20 degrees C on a NMR spectrometer (Varian Inova) operating at 500 MHz. Longitudinal relaxation times were obtained by the conventional inversion-recovery method and the DOSY experiments were carried out using the BPPSTE sequence. The kinetics of complexation revealed that 30 h is enough for stabilization of the NFOH absorbance in presence of cyclodextrin. Solubility isotherm studies show a favorable complexation and increase in solubility when NFOH interacts with cyclodextrin. The analysis of the NMR-derived diffusion coefficients and T(1) relaxation times shows that in the presence of DM-beta-CD, NFOH decreases its mobility in solution, indicating that this antichagasic compound interacts with the cyclodextrin cavity. The release kinetics assays showed that NFOH changes its release profile when in the presence of cyclodextrin due to complexation. This study was focused on the physicochemical characterization of drug-delivery formulations that may serve as potentially new therapeutic options for the treatment of Chagas' disease.

References

  1. J Pharm Biomed Anal. 1997 Jun;15(9-10):1603-19 - PubMed
  2. Int J Pharm. 2005 Sep 30;302(1-2):18-28 - PubMed
  3. J Pharm Biomed Anal. 1997 Oct;16(2):263-8 - PubMed
  4. Int J Pharm. 2007 Feb 22;331(1):99-106 - PubMed
  5. Eur J Pharm Sci. 2008 Jan;33(1):60-71 - PubMed
  6. Bioorg Med Chem. 2003 Nov 3;11(22):4779-83 - PubMed
  7. Can J Anaesth. 2004 Jun-Jul;51(6):566-72 - PubMed
  8. Rev Bras Anestesiol. 2005 Jun;55(3):316-28 - PubMed
  9. Biophys Chem. 2005 May 1;115(1):11-8 - PubMed
  10. Carbohydr Res. 2002 Apr 30;337(9):841-9 - PubMed
  11. J Pharm Sci. 1996 Oct;85(10):1017-25 - PubMed
  12. J Pharm Biomed Anal. 2006 Jun 16;41(4):1428-32 - PubMed
  13. Chem Rev. 1997 Aug 5;97(5):1325-1358 - PubMed
  14. J Pharm Sci. 1996 Nov;85(11):1142-69 - PubMed
  15. Rev Bras Anestesiol. 2003 Sep;53(5):663-71 - PubMed

Publication Types